

Figure 1: High resolution mass spectrum of Ex.3 (method B1)




Figure 2: High resolution mass spectrum of Ex.7 (method B1)




Figure 3: High resolution mass spectrum of Ex.10 (method B1)




Figure 4: High resolution mass spectrum of Ex.14 (method B1)




Figure 5: High resolution mass spectrum of Ex.20 (method B1)




Figure 6: High resolution mass spectrum of Ex.23 (method B1)




Figure 7: *In vivo* efficacy of Ex.3 against MDA-MB-231 xenograft in SCID mice




Figure 8: *In vivo* efficacy of Ex.7 against MDA-MB-231 xenograft in SCID mice




Figure 9: *In vivo* efficacy of Ex.10 against MDA-MB-231 xenograft in SCID mice




Figure 10: *In vivo* efficacy of Ex.14 against MDA-MB-231 xenograft in SCID mice




Figure 11: *In vivo* efficacy of Ex.20 against MDA-MB-231 xenograft in SCID mice




Figure 12: *In vivo* efficacy of Ex.23 against MDA-MB-231 xenograft in SCID mice




Figure 13: *In vivo* PK profile of ADC1 following a single i.v. administration in SCID mice (10 mg/kg)




Figure 14: *In vivo* PK profile of ADC1 following a single i.v. administration in non-rodent species (2.5 mg/kg)




Figure 15: *In vivo* PK profile of Ex.3 following a single i.v. administration in SCID mice (5 mg/kg)




Figure 16: *In vivo* PK profile of Ex.7 following a single i.v. administration in SCID mice (5 mg/kg)




Figure 17: HRMS spectrum of deglycosylated ADC1 at 96 h following a single i.v. administration in SCID mice at 10 mg/kg (method B2)




Figure 18: HRMS spectrum of ADC2 light chain at 96 h following a single i.v. administration in SCID mice at 10 mg/kg (method B2)




Figure 19: HRMS spectrum of deglycosylated ADC1 at 6 d following a single i.v. administration in non-rodent species at 5 mg/kg (method B2)




Figure 20: HRMS spectrum of Ex.3 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)




Figure 21: HRMS spectrum of Ex.7 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)




Figure 22: HRMS spectrum of Ex.10 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)




Figure 23: HRMS spectrum of Ex.14 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)




Figure 24: HRMS spectrum of Ex.20 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)




Figure 25: HRMS spectrum of Ex.23 at 96 h following a single i.v. administration in SCID mice at 5 mg/kg (method B2)

